BEFIRADOL FUMARATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H22ClF2N3O.C4H4O4
Molecular Weight	509.93
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C\C(O)=O.CC1=CC=C(CNCC2(F)CCN(CC2)C(=O)C3=CC=C(F)C(Cl)=C3)N=C1

InChI

InChIKey=HCRQBLXXJOROBP-WLHGVMLRSA-N

InChI=1S/C20H22ClF2N3O.C4H4O4/c1-14-2-4-16(25-11-14)12-24-13-20(23)6-8-26(9-7-20)19(27)15-3-5-18(22)17(21)10-15;5-3(6)1-2-4(7)8/h2-5,10-11,24H,6-9,12-13H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+

HIDE SMILES / InChI

Molecular Formula	C20H22ClF2N3O
Molecular Weight	393.858
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C4H4O4
Molecular Weight	116.0722
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.prlog.org/12758787-fda-approves-neurolixis-ind-application-for-clinical-trial-with-nlx-112-in-parkinsons-disease.html | http://www.pmlive.com/pharma_news/cancer_pain_opioids_set_to_dominate_602759 | https://adisinsight.springer.com/drugs/800019600 | http://neurolixis.com/images/stories/nlx_pf_license_23sept13.pdf

Befiradol (also known as NLX-112) was initially developed by Pierre Fabre as a selective serotonin-1A receptor agonist for the treatment of cancer pain and neuropathic pain. However, these trials were discontinued. In 2013, the development and commercialization rights were licensed to Neurolixis. Neurolixis studied befiradol in Parkinson’s disease (PD) patients that exhibit dyskinesia. Dyskinesia is a side effect that appears after several years of action Levodopa, a drug that remains the gold standard treatment for PD. In 2019, FDA gave a positive response to Neurolixis’s befiradol to be tested in Phase 2 clinical in Parkinson's disease patients suffering from debilitating levodopa-induced dyskinesia.

Originator

Approval Year

PubMed

Title	Date	PubMed
High-efficacy 5-HT1A receptor activation causes a curative-like action on allodynia in rats with spinal cord injury.	2004 Aug 16	15321732
Conformational analysis and crystal structure of {[1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4yl]methyl}[(5-methylpyridin-2-yl)methyl]amine, fumaric acid salt.	2005 Nov	16257736
[(3)H]-F13640, a novel, selective and high-efficacy serotonin 5-HT(1A) receptor agonist radioligand.	2010 Oct	20799027

Patents

Substance Class	Chemical Created by `admin` on `Sun Dec 18 15:44:47 UTC 2022` Edited by `admin` on `Sun Dec 18 15:44:47 UTC 2022`
Record UNII	87C9853CSK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BEFIRADOL FUMARATE

Common Name

English

F-13,640 FUMARATE

Code

English

NLX-112 FUMARATE

Code

English

METHANONE, (3-CHLORO-4-FLUOROPHENYL)(4-FLUORO-4-((((5-METHYL-2-PYRIDINYL)METHYL)AMINO)METHYL)-1-PIPERIDINYL)-, (2E)-2-BUTENEDIOATE (1:1)

Systematic Name

English

F-13640 FUMARATE

Code

English

Code System Code Type Description

CAS

208110-65-0

Created by admin on Sun Dec 18 15:44:47 UTC 2022 , Edited by admin on Sun Dec 18 15:44:47 UTC 2022

PRIMARY

FDA UNII

87C9853CSK

Created by admin on Sun Dec 18 15:44:47 UTC 2022 , Edited by admin on Sun Dec 18 15:44:47 UTC 2022

PRIMARY

PUBCHEM

10229295

Created by admin on Sun Dec 18 15:44:47 UTC 2022 , Edited by admin on Sun Dec 18 15:44:47 UTC 2022

PRIMARY

Related Record Type Details


					RAT9OHA1YH

BEFIRADOL

PARENT -> SALT/SOLVATE

Related Record Type Details


					RAT9OHA1YH

BEFIRADOL

ACTIVE MOIETY